ACTICOAT^◊ Moisture Control (with SILCRYST™ Nanocrystals) is an absorbent 3-layer dressing consisting of the following:  A nanocrystalline silver-coated polyurethane layer, a white polyurethane foam layer and a blue waterproof polyurethane film layer.  ACTICOAT^◊ Moisture Control provides an effective barrier to bacterial penetration.  In the presence of exudate the dressing will help maintain a moist wound environment.  ACTICOAT^◊ Moisture Control may be left in place over a wound for up to 7 days.

• New ACTICOAT^◊ Moisture Control eliminates threats to healing.
• Powerful antimicrobial barrier protection.
• Waterproof film with visible strikethrough indicates when dressing change is required.
• Highly absorbent hydrocellular technology wicks away excess exudate.
• Patented nanocrystalline technology sets ACTICOAT^◊ apart with proven bactericidal activity.
• Non-adhesive wound contact layer allows minimal pain on removal.
• Extra cushioning maximizes comfort.
• Easy to apply and remove.
• No hydration or cover dressing required.
• Maintains shape for faster, cleaner dressing changes.
• Provides 7-day wear time.

• Provides fast-acting, long-lasting antimicrobial barrier control.
• Effective barrier which may assist in preventing contamination of the wound.
• Laboratory studies show that the ACTICOAT^◊ dressing kills micro-organisms faster than conventional products such as silver sulfadiazine (1 percent cream) or silver nitrate (0.5%) solution.  It has also been shown in-vitro to provide protection against more than 150 pathogens.  The pathogens tested in the lab include very resistant strains of bacteria such as antibiotic-resistant strains of Pseudomonas, methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus and fungi.  These pathogens have been known to sweep through a hospital and infect a great many patients with already weakened immune systems.  Infections contracted during hospitalization caused by these so-called superbugs and other organisms cost North American taxpayers an estimated $18 billion a year in additional hospital care.
• ACTICOAT^◊ is versatile.  The dressings can be cut to the desired shape and size to wrap around all body parts.
• The sustained release of silver also means fewer dressing changes, resulting in less exposure of the wound bed to the environment.

ACTICOAT^◊ Moisture Control Dressing is indicated for use in light to moderately exuding partial and full thickness wounds including decubitus ulcers, diabetic ulcers, 1st and 2nd degree burns, and donor sites.  ACTICOAT^◊ Moisture Control may be used over debrided and partial thickness wounds.

Contraindications

• Do not use on patients with a known sensitivity to silver.
• Do not use on patients during MRI (Magnetic Resonance Imaging) examination.

Precautions

• For external use only.
• ACTICOAT^◊ Moisture Control is not compatible with oil-based products such as petrolatum.
• ACTICOAT^◊ Moisture Control may not be compatible with topical antimicrobials.
• Do not use ACTICOAT^◊ Moisture Control with saline.
• ACTICOAT^◊ Moisture Control is not compatible with oxidizing agents (eg. EUSOL) as these can break down the absorbent polyurethane component of the dressing.
• Avoid contact with electrodes or conductive gels during electronic measurements eg. EEG and ECG.
• If reddening or sensitization occurs, discontinue use.
• ACTICOAT^◊ Moisture Control Dressings are not intended to provide treatment for infected wounds.  ACTICOAT^◊ Moisture Control Dressings may be used on infected wounds which are being managed in accordance with institutional clinical protocols for infection abatement as an adjunct to the standard treatment regimen to provide a barrier to bacterial penetration.

Product#	Size	Pcs/Pkg	Pkg/Case	HCPCS Code
20111	2 x 2	10	7	A6209
20311	4 x 4	10	7	A6209
20411	4 x 8	10	7	A6210

™SILCRYST is a Trademark of NUCRYST Pharmaceuticals Corp. used under license.